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ABSTRACT
ObjeCtive
To assess the benefits and risks of short term (<12 
months) or extended (>12 months) dual antiplatelet 
therapy (DAPT) versus standard 12 month therapy, 
following percutaneous coronary intervention with 
drug eluting stents.
Design
Meta-analysis of randomised controlled trials.
Data sOurCes 
PubMed, Embase, Cumulative Index to Nursing and 
Allied Health Literature, Scopus, Web of Science, 
Cochrane Library, and major congress proceedings, 
searched from 1 January 2002 to 16 February 2015.
review methODs
Trials comparing short term (<12 months) or extended 
(>12 months) DAPT regimens with standard 12 month 
duration of therapy. Primary outcomes were 
cardiovascular mortality, myocardial infarction, stent 
thrombosis, major bleeding, and all cause mortality.
results
10 randomised controlled trials (n=32 287) were 
included. Compared to 12 month DAPT, a short term 
course of therapy was associated with a significant 
reduction in major bleeding (odds ratio 0.58 (95% 
confidence interval 0.36 to 0.92); P=0.02) with no 
significant differences in ischaemic or thrombotic 
outcomes. Extended versus 12 month DAPT yielded a 
significant reduction in the odds of myocardial 
infarction (0.53 (0.42 to 0.66); P<0.001) and stent 
thrombosis (0.33 (0.21 to 0.51); P<0.001), but more 
major bleeding (1.62 (1.26 to 2.09); P<0.001). All cause 
but not cardiovascular death was also significantly 
increased (1.30 (1.02 to 1.66); P=0.03).
COnClusiOns
Compared with a standard 12 month duration, short 
term DAPT (<12 months) after drug eluting stent 
implementation yields reduced bleeding with no 
apparent increase in ischaemic complications, and 
could be considered for most patients. In selected 
patients with low bleeding risk and very high ischaemic 
risk, extended DAPT (>12 months) could be considered. 
The increase in all cause but not cardiovascular death 
with extended DAPT requires further investigation.
Introduction
Drug eluting stents have consistently improved the safety 
and efficacy of percutaneous coronary intervention as 
compared with bare metal stents.1-4  While drug eluting 
stents have reduced in-stent restenosis, uncertainty has 
arisen regarding the risk of associated late and very late 
stent thrombosis. Dual antiplatelet therapy consisting of 
aspirin plus a P2Y12 receptor antagonist is recommended 
after drug eluting stent implantation for at least 
12 months by the American College of Cardiology/Ameri-
can Heart Association and for six to 12 months by Euro-
pean guidelines,5 6 followed by aspirin monotherapy. 
Current recommendations, however, are based largely on 
observational data with few randomised controlled trials. 
The most recent trials and meta-analyses have sug-
gested comparable efficacy of short term dual antiplate-
let therapy versus therapy of at least 12 months, 
especially with newer generation drug eluting stents,7-9 
but these studies are underpowered to draw definitive 
conclusions. On the other hand, very late stent throm-
bosis still occurs with drug eluting stents, especially 
after first generation devices, raising the question of 
whether prolongation of dual antiplatelet therapy offers 
clinical benefit. One randomised controlled trial 
recently showed a significant reduction of stent throm-
bosis with dual antiplatelet therapy extended beyond 
12 months at the price of increased bleeding.10 Thus, the 
optimal duration of dual antiplatelet therapy is 
debated, with short term and extended protocols not 
yet compared to standard 12 month treatment within 
the same trial. We aimed to perform a meta-analysis of 
randomised controlled trials to compare the efficacy 
and safety of short term and extended dual antiplatelet 
therapy with standard 12 month therapy.
Methods
Data sources and search strategy
Established methods were used in compliance with the 
Preferred Reporting Items for Systematic reviews and 
WhAT IS AlReAdy knoWn on ThIS TopIC
Dual antiplatelet therapy is currently recommended after the implantation of drug 
eluting stents, but the optimal duration is a matter of debate
The currently recommended 12 month duration is of uncertain value
WhAT ThIS STudy AddS
Compared with a 12 month duration, short term (<12 months) dual antiplatelet 
therapy yields reduced bleeding without increasing ischaemic complications
Dual antiplatelet therapy extended beyond 12 months reduces ischaemic and 
thrombotic events compared with a 12 month regimen, but at the price of greater 
risk of major bleeding and all cause death
The increase in all cause but not cardiovascular death seen with extended therapy 
requires further investigation
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Meta-Analyses (PRISMA) statement in healthcare inter-
ventions.11 We screened Medline, Embase, the Cumula-
tive Index to Nursing and Allied Health Literature, 
Scopus, Web of Science, the Cochrane Register of Con-
trolled Clinical Trials, as well as congress proceedings 
from major cardiac societies, for randomised data com-
paring different durations of dual antiplatelet therapy. 
Dual antiplatelet therapy was defined as aspirin plus a 
P2Y12 receptor inhibitor, after percutaneous coronary 
intervention with implantation of a drug eluting stent. 
The search period took place from 1 January 2002 to 16 
February 2015. 
Search terms according to medical subjects headings 
were: “DAPT”, “dual antiplatelet therapy”, “clopidogrel”, 
“Plavix”, “prasugrel”, “Efient”, “ticagrelor”, “Brilinta”, 
“thienopyridine”, “P2Y12”, “shortened DAPT”, “pro-
longed DAPT”, “extended DAPT”, “premature cessation”, 
“early discontinuation”, “randomised trial”, and “trial”. 
No language or publication status restriction was 
imposed. The most updated or inclusive data for each 
study were used for abstraction. In addition, landmark 
analysis data at 12 months were available from the origi-
nal PROlonging Dual antIplatelet treatment after Grading 
stent-induced intimal hyperplasia studY (PRODIGY)7 and 
were therefore incorporated into the present article.
study design and selection criteria
The design of the current meta-analysis compared two 
strategies of dual antiplatelet therapy involving three 
durations after percutaneous coronary intervention 
with drug eluting stent implantation. The first compar-
ison was between a short term (<12 months) and 
12 month therapy, and the second between an extended 
duration (>12 months) and 12 month therapy. The origi-
nal PRODIGY randomised controlled trial7 assigned 
patients to either six or 24 month durations. Because 
the randomisation process in PRODIGY began one 
month after the index percutaneous coronary interven-
tion, the availability of landmark data at 12 months 
allowed inclusion of the study in the short term versus 
12 month comparison, after censoring events that 
occurred after 12 months and keeping the original ran-
domisation design. We did additional sensitivity analy-
ses by including PRODIGY trial data in the extended 
duration versus 12 month comparison. The analyses 
included only events that occurred beyond 12 months in 
both study arms (postrandomisation subgroups). 
The main exclusion criteria for this meta-analysis 
were: observational design, patients without docu-
mented coronary artery disease or patients with periph-
eral or cerebrovascular disease, percutaneous coronary 
intervention without stents or with bare metal stents 
only, and duration timeframes of dual antiplatelet ther-
apy selected by the meta-analysis not reported. Two 
independent reviewers (VS and MK) selected the stud-
ies for inclusion and extracted the study characteristics 
and relevant outcomes; divergences were solved by con-
sensus after discussion with a third reviewer (EPN). Three 
authors (EPN, MK, and VS) independently reassessed the 
trials’ eligibility and ranked their risk of bias. Risk of bias 
was graded using the components recommended by the 
Cochrane Collaboration—that is, random sequence 
generation; allocation concealment; blinding of partic-
ipants, personnel, and outcome assessors; incomplete 
outcome data; selective outcome reporting; and other 
sources of bias.12
Outcome measures
Primary clinical endpoints were cardiovascular mortal-
ity, myocardial infarction, stent thrombosis, major 
bleeding, and overall mortality; secondary endpoints 
were repeat revascularisation, and cerebrovascular acci-
dent, and the combination of cardiac and cerebrovascu-
lar accidents. We classified stent thrombosis as definite/
probable, definite, late (between 30 days and one year 
after percutaneous coronary intervention), and very late 
(>one year after percutaneous coronary intervention) 
according to criteria from the Academic Research Con-
sortium.13  For major bleeding, trial definitions were 
applied. Major bleeding according to TIMI criteria,14 and 
a composite endpoint of major adverse cardiac and cere-
brovascular accidents were also assessed.
statistical analyses
Data were analysed according to the intention to treat 
principle. Odds ratios and 95% confidence intervals 
were used as summary statistics. Heterogeneity was 
assessed by Cochran’s Q test.15 We also used the statisti-
cal inconsistency test (I2=(Q−df)/Q×100%, where Q=χ2 
statistic and df=its degrees of freedom) to overcome the 
low statistical power of Cochran’s Q test. Pooled odds 
ratios were calculated using a fixed effect model with 
the Mantel-Haenszel method, because of the absence of 
moderate or significant inconsistency (>50%) across 
studies. We also did prespecified sensitivity analyses 
using a random effects model. Potential publication 
bias was examined by constructing funnel plots for the 
clinical outcomes in which the standard error of the log 
of the odds ratio was plotted against the odds ratio. The 
asymmetry of the plot was estimated both visually and 
by Harbord’s regression test.16 Prespecified analyses 
assessed the effect of different durations of dual anti-
platelet therapy in the following subgroups: age older 
than 65 years or younger than 65 years, patients with or 
without acute coronary syndrome, and those treated 
with either clopidogrel or new P2Y12 inhibitors (prasu-
grel and ticagrelor). P<0.05 was considered significant 
and reported as two sided.
Results
studies and patients
The PRISMA statement flowchart (web fig 1) describes 
the literature screening, study selection, and reasons for 
exclusion. From 338 initial studies, 295 were discarded 
at title or abstract level. Another 33 studies did not meet 
the prespecified inclusion criteria and were therefore 
excluded. A total of 10 randomised controlled trials 
(n=32 287)7 8 10 17-28  were finally included in the meta-anal-
ysis. Tables 1  and 2  list the characteristics and refer-
ences of the included studies. Web fig 2 summarises the 
quality of included studies, along with potential sources 
of bias. Web table 1 outlines the full electronic Medline 
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search process. No publication bias was suggested by 
the funnel plots (web figs 3-8) and by Harbord’s regres-
sion test (web table 7). Seven studies tested short term 
regimens (<12 months) of dual antiplatelet therapy against 
12 months’ duration (table 1),7 8 22–28  and three studies 
tested extended regimens (>12 months; table 2).10 17-21
Clopidogrel and aspirin was the most frequent drug 
combination in dual antiplatelet therapy; prasugrel or 
ticagrelor were available in three8 10 17-19  and two8-28 
studies, respectively. Of 32 287 patients, 7975 were ran-
domly allocated to short term regimens and 8196 to 
extended regimens of dual antiplatelet therapy; 16 116 
patients constituted the 12 month control group. Web 
table 2 lists the patients’ baseline characteristics. 
Patients presented evenly, with either stable angina/
silent ischaemia or non-ST segment elevation acute cor-
onary syndrome (48% and 45%, respectively); fewer than 
10% presented with ST segment elevation myocardial 
infarction. Web table 3 lists procedural characteristics 
of each study. Web table 4 lists definitions of major 
adverse cardiac and cerebrovascular events.
Cardiovascular mortality and myocardial infarction
Eight studies including 26 996 patients provided data 
for cardiovascular mortality. Cardiovascular mortality 
after short term and 12 month dual antiplatelet therapy 
did not differ significantly (event rate 1.13% (68/5997 
patients) v 1.20% (72/6013); odds ratio 0.95 (95% confi-
dence interval 0.68 to 1.33); P=0.76; I2=0%; fig 1). Simi-
larly, cardiovascular mortality did not differ 
significantly between extended dual antiplatelet ther-
apy and 12 month therapy (1.03% (78/7551) v 0.95% 
(71/7455); 1.09 (0.79 to 1.50); P=0.62; I2=34%; fig 1).
All 10 randomised controlled trials (n=32 287) were 
included in the myocardial infarction analysis. Myocar-
dial infarction rates were similar in patients ran-
domised to either short term or 12 month dual 
antiplatelet  therapy (1.65% (132/7975 patients) v 1.50% 
(120/8020); odds ratio 1.11 (95% confidence interval 0.87 
to 1.43); P=0.40; I2=0%; fig 1). We saw a reduction of 
roughly 50% in the odds of myocardial infarction with 
extended dual antiplatelet therapy, compared with 12 
month therapy (1.55% (127/8196) v 2.89% (234/8096); 
0.53 (0.42 to 0.66); P<0.001; I2=37%; fig 1).
stent thrombosis
All 10 studies (n=32 287) contributed to the analysis of 
definite/probable stent thrombosis (fig 2). We saw no sig-
nificant difference in the rates of stent thrombosis when 
comparing short term dual antiplatelet therapy with 
12  month therapy (0.53% (42/7975 patients) v 0.40% 
(32/8020); odds ratio 1.32 (95% confidence interval 0.83 
to 2.08); P=0.24; I2=0%). Similarly, the analysis of defi-
nite stent thrombosis demonstrated identical rates 
(0.3%) for both short term and 12 month dual antiplate-
let therapy (1.00 (0.40 to 2.53); P=0.99; I2=0%; fig 2).
By contrast, a 67% reduction in the odds of definite/
probable stent thrombosis was observed with extended 
versus 12 month dual antiplatelet therapy (odds ratio 0.33 
(95% confidence interval 0.21 to 0.51); P<0.001; I2=18%; 
fig 2). The corresponding rates were 0.32% (26/8196 
patients) versus 0.98% (79/8096), with a number needed 
table 2 | Characteristics of included studies comparing extended (>12 month) versus 12 month dual antiplatelet therapy 
inclusion criteria exclusion criteria Primary endpoints secondary endpoints
time to 
randomisation
arCtiC interruption17 18 (2014), n=1286, 12 months v 18 months of DaPt duration*
≥18 years and eligible for 
PCI with planned use of 
≥1 DES; without use of a 
GPIIb/IIIa inhibitor at 
randomisation; able to 
understand study 
requirements and comply 
with study procedures 
and protocol
Anticoagulation with vitamin K antagonists; contraindication 
to aspirin or clopidogrel, GPIIb/IIIa inhibitors, or increased 
dose regimen of aspirin/clopidogrel; ongoing or recent 
bleeding or major surgery <3 weeks; severe liver insufficiency; 
thrombocytopenia <80 000/μL; GPIIb/IIIa inhibitor before 
randomisation; primary PCI for STEMI; history of major 
bleeding with contraindication to APT; scheduled surgery <12 
months; high risk feature of poor compliance to DAPT
Composite of all 
cause death, MI, 
stroke or TIA, urgent 
coronary 
revascularisation, 
and ST
Composite of ST (whether 
revascularised or not) and urgent 
revascularisation, all cause death, MI, 
stroke or TIA, urgent coronary 
revascularisation, and ST; main safety 
endpoint was STEEPLE major bleeding
12 months after 
index PCI
DaPt10 19 (2014), n=9961, 12 months v 30 months of DaPt duration
>18 years old, 
undergoing 
percutaneous 
intervention with stent 
deployment
Index procedure stent placement with stent diameter <2.25 
mm or >4.0 mm; pregnancy; planned surgery necessitating 
discontinuation of APT within 30 months after enrollment; life 
expectancy of <3 years; enrollment in another device or drug 
study whose protocol specifically rules out concurrent 
enrollment or involves blinded placement of a DES or BMS 
other than those included as DAPT study devices; warfarin or 
similar anticoagulant therapy; hypersensitivity or allergies to 
one of the drugs or DES components; patient treated with 
both DES and BMS during index procedure
Definite/probable ST 
and MACCE defined 
as composite of 
death, MI or stroke
Moderate or severe bleeding according 
to GUSTO14 classification; clinically 
actionable non-CABG related bleeding 
according to BARC (type 2, 3, and 5); MI, 
stroke, cardiac and vascular mortality
12 months after 
index PCI
Des late20 21 (2010), n=5045, 12 months v 24 months of DaPt duration
<12 months DES 
implantation; no MACE 
(MI, stroke, repeat PCI) or 
major bleeding since PCI; 
DAPT on board
DAPT contraindications due to bleeding diathesis or major 
bleeding history; long term DAPT indication due to 
concomitant vascular disease or recent ACS
MI or cardiac death All cause death; MI, stroke; ST; repeat 
revascularisation; composite of MI or all 
cause death; composite of MI, stroke, or 
all cause death; composite of MI, stroke, 
or cardiac death; TIMI14 major bleeding
12 months after 
index PCI
Data classified by study name (year), no of patients, and comparison of DAPT durations after index percutaneous coronary intervention. DAPT=dual antiplatelet therapy; PCI=percutaneous 
coronary intervention; DES=drug eluting stent; GP=glycoprotein; STEMI=ST segment elevation myocardial infarction; APT=antiplatelet therapy; MI=myocardial infarction; ST=stent thrombosis; 
TIA=transient ischaemic attack; STEEPLE=the safety and efficacy of enoxaparin in PCI patients, an international randomized evaluation; BMS=bare-metal stent; MACCE=major adverse cardiac 
and cerebrovascular events; GUSTO=global utilization of streptokinase and TPA for occluded arteries; CABG=coronary artery bypass grafting; BARC=Bleeding Academic Research Consortium; 
MACE=major adverse cardiovascular events; ACS=acute coronary syndrome.
*Available landmark data at 12 and 12-24 months.
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to treat of 152. Similarly, the analysis of definite stent 
thrombosis showed a 70% reduction in the odds of stent 
thombosis with extended versus 12 month dual antiplate-
let therapy (0.30 (0.19 to 0.49); P<0.001; I2=32%; corre-
sponding rates 0.27% (22/8196) v 0.89% (72/8096; fig 2).
Timing of stent thrombosis
We saw similar rates of late stent thrombosis when com-
paring short term with 12 month dual antiplatelet therapy 
(0.36% (20/5501 patients) v 0.31% (16/5089); odds ratio 
1.24 (95% confidence interval 0.65 to 2.36); P=0.50; 
I2=40%). By contrast, the odds of very late stent thrombo-
sis were significantly reduced by 67% when comparing 
extended with 12 month therapy (0.32% (26/8196) v 0.98% 
(79/8096); 0.33 (0.21 to 0.51); P<0.001; I2=18%; fig 2).
major bleeding
Major bleeding rates were available in all studies 
(n=32 287). Short term versus 12 month dual 
 antiplatelet therapy was associated with a roughly 
40% reduction in the odds of major bleeding (event 
rate 0.35% (28/7975 patients) v 0.61% (49/8020); odds 
ratio 0.58 (95% confidence interval 0.36 to 0.92); 
P=0.02; I2=0%); the corresponding number needed to 
treat to prevent a major bleed was 385. Conversely, 
continuation of dual antiplatelet therapy beyond 12 
months significantly increased the odds of major 
bleeding by 62% (1.95% (160/8196) v 1.21% (98/8096); 
1.62 (1.26 to 2.09); P<0.001; I2=7%; fig 3); the corre-
sponding number needed to harm by causing a major 
bleed was 135.
all cause mortality
All 10 randomised controlled trials (n=32 287) provided 
data for all cause death. We found no significant differ-
ences in all cause mortality between short term and 
12 month dual antiplatelet therapy (event rate 1.43% 
(114/7975 patients) v 1.56% (125/8020); odds ratio 0.91 
Cardiovascular mortality
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  PRODIGY7,26
  RESET27
  SECURITY8
Total (95% CI)
Test for heterogeneity: χ2=1.40, df=5, P=0.92, I2=0%
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Fig 1 | individual and summary odds ratios for the endpoints of cardiovascular mortality and myocardial infarction. 
m-h=mantel-haenszel. Data stratified by duration of dual antiplatelet therapy: short term (<12 months) versus 12 months, 
and extended (>12 months) versus 12 months
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(95% confidence interval 0.71 to 1.18); P=0.49; I2=0%; 
fig 4). By contrast, extended versus 12 month dual anti-
platelet therapy was associated with a higher risk of all 
cause death (1.84% (151/8196) v 1.42% (115/8096); 1.30 
(1.02 to 1.66); P=0.03; I2=0%; fig 4). The number needed 
to harm was 238.
repeat revascularisation and cerebrovascular 
accidents
Repeat revascularisation data were available from 
seven studies (n=16 351). Short term duration of dual 
antiplatelet therapy yielded similar results compared 
with 12 month duration (event rate 3.06% (153/4994 
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Fig 2 | individual and summary odds ratios for the endpoints of definite/probable stent thrombosis and definite stent 
thrombosis, and analysis of late and very late stent thrombosis. Data stratified by duration of dual antiplatelet therapy: 
short term (<12 months) versus 12 months, and extended (>12 months) versus 12 months 
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patients) v 2.63% (132/5026); odds ratio 1.17 (95% confi-
dence interval 0.92 to 1.48); P=0.20; I2=0%). Results 
with extended dual antiplatelet therapy were compara-
ble to those with 12 month therapy (2.80% (89/3176) v 
2.35% (74/3155); 1.20 (0.88 to 1.64); P=0.25; I2=0%; fig 5).
All studies (n=32 287) provided data for cerebrovascu-
lar accidents. These events occurred in 0.45% of 
patients (36/7975) with short term dual antiplatelet 
therapy versus 0.49% (39/8020) with 12 month therapy 
(odds ratio 0.93 (95% confidence interval 0.59 to 1.46); 
P=0.75; I2=0%). Similarly, we did not see any significant 
differences in cerebrovascular accidents when compar-
ing extended duration with 12 month duration (0.78% v 
0.84%; 0.93 (0.66 to 1.31); P=0.67; I2=0%; web fig 9).
sensitivity analyses
The results obtained by repeating the analyses using 
random effects models were highly consistent with the 
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Fig 3 | individual and summary odds ratios for the endpoint of major bleeding. Data stratified by duration of dual 
antiplatelet therapy: short term (<12 months) versus 12 months, and extended (>12 months) versus 12 months
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Fig 4 | individual and summary odds ratios for the endpoint of all cause mortality. Data stratified by duration of dual 
antiplatelet therapy: short term (<12 months) versus 12 months, and extended (>12 months) versus 12 months
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main findings (web table 5). Seven studies (n=17 716) 
reported major bleeding events by TIMI criteria.14 Short 
term dual antiplatelet therapy compared with 12 month 
therapy was associated with a significantly reduced rate 
of TIMI major bleeding (odds ratio 0.49 (95% confi-
dence interval 0.26 to 0.94); P=0.03; I2=0%). Converse 
results were found with therapy continuation beyond 12 
months compared with 12 month therapy (1.60 (0.97 to 
2.64); P=0.07; I2=42%; web fig 10).
Nine studies reported the incidence of major adverse 
cardiac and cerebrovascular accidents. No significant 
differences were seen with short term versus 12 month 
dual antiplatelet therapy (odds ratio 1.02 (0.86 to 1.22); 
P=0.81; I2=0%). The odds of major adverse cardiac and 
cerebrovascular accidents were significantly reduced 
by 22%, when extended therapy was compared with 12 
month therapy (0.78 (0.67 to 0.92); P=0.002; I2=47%; 
web fig 11). Analyses in patients with and without acute 
coronary syndrome, younger or older than 65 years, and 
treated with different P2Y12 inhibitors (web table 6) 
showed no significant outcome differences among 
those subgroups. Sensitivity analyses for the extended 
versus 12 month regimen comparison after inclusion of 
the PRODIGY landmark analysis are in web figs 12-18. 
These analyses showed highly consistent findings with 
the main results, except for all cause mortality, which 
became of borderline significance (P=0.05) in the 
extended versus 12 month regimen comparison.
discussion
The current meta-analysis compares the efficacy and 
safety of three different durations of dual antiplatelet 
therapy in patients undergoing percutaneous coronary 
intervention with drug eluting stents. To our knowl-
edge, by its unique design, it is the first report focusing 
on outcomes with either short term or extended (beyond 
12 months) duration of dual antiplatelet therapy versus 
12 month therapy. By incorporating the most recent 
 evidence from randomised controlled trials, this report 
forms the largest database on duration of dual anti-
platelet therapy ever analysed (n=32 287). 
There were two main findings. First, short term dual 
antiplatelet therapy, when compared to 12 month ther-
apy, was associated with a similar rate of stent throm-
bosis or myocardial infarction, with a reduced risk of 
major bleeding. Second, extended therapy, compared 
with a 12 month regimen, reduced the odds of definite/
probable stent thrombosis, very late stent thrombosis, 
and myocardial infarction, but increased the odds of 
major bleeding. While all cause mortality also increased 
in the extended versus 12 month regimen comparison, 
driven by non-cardiovascular events, this study finding 
becomes mitigated by the inclusion of the landmark 
analysis at 12 months of patients enrolled in the PROD-
IGY trial. Nevertheless, given the potential profound 
implications of this observation if confirmed to be true, 
further studies are needed to validate or confute this 
preliminary finding.
Coronary drug eluting stents—by inhibiting in-stent 
neointimal proliferation—have effectively reduced the 
need for repeat revascularisation compared with bare 
metal stents and have achieved widespread use 
worldwide.4  Concerns about drug eluting stents have 
arisen, however, regarding the propensity for throm-
botic events occurring more than one year after 
implantation.1 2
Based on these considerations, current guidelines 
from the American College of Cardiology/American 
Heart Association advocate at least 12 months of dual 
antiplatelet therapy after implantation of drug eluting 
stents.5  The European Society of Cardiology endorses 
six to 12 months of dual therapy after implantation, and 
12 months for all patients with acute coronary syn-
drome irrespective of revascularisation strategy.6  Pro-
longed dual antiplatelet therapy (beyond 12 months), 
while protecting against thrombosis, will invariably 
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Fig 5 | individual and summary odds ratios for the endpoint of repeat revascularisation. Data stratified by duration of dual 
antiplatelet therapy: short term (<12 months) versus 12 months, and extended (>12 months) versus 12 months
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increase the risk of major bleeding with an uncertain 
net impact on patient outcomes after percutaneous cor-
onary intervention.29-31 This benefit-risk dualism has 
raised controversies around the optimal duration of 
dual antiplatelet therapy that would maximise the 
effect against stent thrombosis while minimising the 
associated bleeding risk. As a result, recent randomised 
controlled trials have adopted a triad of duration mod-
els: short term, 12 months, and beyond 12 months.
short term (<12 month) versus 12 month dual 
antiplatelet therapy
We did not observe any significant differences in myo-
cardial infarction and stent thrombosis outcomes with 
short term dual antiplatelet therapy as compared with 
12 month therapy, in the face of reduced bleeding com-
plications. This neutral effect on ischaemic endpoints 
testifies for a similar efficacy and a greater safety profile 
with shortened therapy as compared with 12 month 
therapy. Our findings are consistent with those of recent 
trials (which were, however, limited in sample size) and 
two previous meta-analyses of four trials comparing 
short term with longer durations.9 32 The two analyses, 
however, included fewer studies that were, in addition, 
heterogeneous as to duration of prolonged dual anti-
platelet therapy, spanning 12-24 months.
extended (>12 month) versus 12 month dual 
antiplatelet therapy
Although previous studies had suggested that short 
term dual antiplatelet therapy is effective and safe, 
especially with the availability of modern interven-
tional techniques and new generation drug eluting 
stents, the benefit to harm ratio of therapy beyond one 
year had remained largely unknown. Registry data had 
suggested improvements in ischaemic outcomes with 
prolonged dual antiplatelet therapy; however, registries 
are prone to bias owing to their observational design.33 34 
An important finding was the 67% reduction in cumula-
tive odds of definite/probable stent thrombosis and, 
specifically, of very late (>1 year) stent thrombosis with 
extended dual antiplatelet therapy when compared 
with 12 month therapy, at the price of higher major 
bleeding and all cause mortality. In practical terms, the 
numbers needed to treat and to harm were similar for 
thrombotic (number needed to treat 152) and bleeding 
(number needed to harm 135) events, highlighting the 
importance of balancing the patients’ thrombotic pro-
file against their bleeding risk in case of prolonged dual 
antiplatelet therapy. 
The pathophysiology of very late stent thrombosis 
has been attributed to incomplete re-endothelialisation 
caused by drug or scaffold induced inhibition of endo-
thelial cell proliferation, belated stent malapposition, 
neoatherosclerosis, and inflammation induced by the 
durable polymers, which occur over time after drug 
eluting stent implantation.35 36  The results of the pres-
ent meta-analysis suggest that in a subgroup of 
patients, both patient and stent related factors can 
interact adversely over time through retarded endothe-
lialisation and persistent inflammation, culminating in 
very late stent thrombosis37 once dual antiplatelet ther-
apy is withdrawn. On the other hand, major bleeding 
and apparently also all cause deaths (number needed to 
harm 238) were more common with prolonged dual 
antiplatelet therapy. It remains unclear whether this 
observation on total mortality is real and whether it 
might be explained by the effect of bleeding on fatal 
outcomes.
The DAPT trial,10 19 which is the largest to explore the 
effect of extended versus 12 month dual antiplatelet 
therapy, found ischaemic protection with extended 
therapy at the price of increased bleeding risk. In the 
present meta-analysis, a large number of myocardial 
infarctions were derived from the DAPT trial, which was 
only partly justified by the trial’s bigger sample size 
than the other trials. Indeed, the annual incidence of 
myocardial infarction in the DAPT trial was more than 
twice that reported by other studies. On the other hand, 
the annual incidence of other thrombotic complications 
(such as stent thrombosis) or of bleeding events in the 
DAPT trial seemed more consistent with those observed 
in the other included trials. Reasons for the marked dif-
ference in myocardial infarction rates—in the range of 
three extra events per 100 aspirin treated patients per 
year in the control group of the DAPT trial as compared 
to the other studies—remain unclear. Moreover, the 
consistency of direction of estimates testified by the 
very low heterogeneity across trials in our pooled anal-
ysis suggests that the overall effect of this meta-analysis 
is robust and can be interpreted with confidence. In 
view of the residual uncertainty on overall mortality 
and the clear bleeding liability associated with pro-
longed dual antiplatelet therapy, a long term regimen 
should probably be reserved to patients at high 
 ischaemic risk and low bleeding risk, in whom such 
treatment would have been well tolerated for the first 
12 months.
implications for clinical practice
There are distinct effects associated with short term and 
extended dual antiplatelet therapy. Shorter duration 
yields fewer bleeding events than a longer duration, 
with comparable efficacy against ischaemic complica-
tions. Furthermore, extended therapy leads to a marked 
reduction of thrombotic complications at the price of 
increased bleeding rates with a signal towards increased 
all cause mortality. The currently recommended 12 
month duration of dual antiplatelet therapy after drug 
eluting stent implementation is a compromise between 
ischaemic and bleeding risks. However, based on this 
meta-analysis, the 12 month recommendation seems to 
be a less appealing strategy to minimise bleeding risk or 
maximise ischaemic benefit than a short term or an 
extended therapy regimen, respectively.
The lack of clear-cut benefits observed with the 12 
month strategy raises the question of whether this aver-
age duration of dual antiplatelet therapy might be 
replaced by a shorter or longer duration in patients at 
high or low bleeding risk, respectively.
The apparently discordant finding of similar isch-
aemic risks in trials comparing a short term versus 
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12  month duration of dual antiplatelet therapy—as 
opposed to an ischaemic protection conferred by an 
extended versus 12 month duration—may reflect differ-
ences in the selection of patient populations included 
in the studies. In trials randomising patients to a 
12  month versus short term regimen, those at high 
bleeding risk were not excluded, and randomisation 
occurred relatively early after stent implantation (that is, 
immediately, or after one, three, or six months). Studies 
comparing 12 month with extended regimens randomised 
patients only after several months of dual antiplatelet 
therapy provided that no major bleeding episodes had 
occurred in the preceding months. These studies most 
likely selected, by design, a patient population at rela-
tively lower risk of bleeding while receiving therapy. 
In view of the possible association between bleeding 
and subsequent ischaemic and fatal events, it may be 
hypothesised that in less carefully selected populations 
(such as those patients included in short term v 12 
month studies), the detrimental effect of bleeding on 
ischaemic endpoints and death would have counterbal-
anced the ischaemic protection potentially offered by 
dual antiplatelet therapy. On the other hand, prolong-
ing therapy in the long term in patients at relatively 
lower bleeding risk (that is, those who tolerate this ther-
apy for at least 12 months) could result in a more favour-
able reduction of ischaemic events, at the cost of some 
major haemorrhagic complications.
From an individual patient’s perspective, the results 
of this article suggest that the 12 month cut-off for dual 
antiplatelet therapy should not necessarily be consid-
ered as the optimal standard of care choice. Rather, 
durations shorter or longer than 12 months should be 
calibrated, taking into consideration the patient’s 
bleeding and ischaemic risk profile, in addition to pro-
cedural variables and acuity of presentation. Further, 
well powered trials are warranted to test the clinical 
effect of tailored dual antiplatelet therapy. A practical 
approach for clinicians, given the results of our pooled 
analysis, would be to offer to many patients, especially 
those at high bleeding risk, a duration of less than one 
year after coronary implantation of a drug eluting stent. 
Prolonged dual antiplatelet therapy beyond one year 
could represent an option for selected patients who 
present very high ischaemic and low bleeding risks.
effect of dual antiplatelet therapy on all cause 
mortality
In the present article, all cause but not cardiovascular 
mortality was found to be increased with extended dual 
antiplatelet therapy as compared with 12 month regi-
mens. These findings were at variance with a recent 
Bayesian non-standard meta-analysis, in which no dif-
ference in all cause, cardiovascular, and non-cardiovas-
cular mortality was found between treatment 
durations.38  The Bayesian meta-analysis focused only 
on the mortality outcome and had broad inclusion crite-
ria. It comprised patients with coronary artery disease 
undergoing medical management (that is, without coro-
nary stent implantation) and patients without coronary 
artery disease, who qualified for inclusion based on 
multiple atherothrombotic risk factors, peripheral artery 
disease, or presence of atrial fibrillation. This recent 
pooled analysis also included a highly heterogeneous 
duration of regimens. Dual antiplatelet therapy spanned 
from six to 40 months in the so-called “extended DAPT” 
arm, which was compared to a similarly heterogeneous 
shorter “DAPT duration” group; this second group 
included not only a shortened regimen but also no dual 
antiplatelet therapy at all. Hence, while the finding of 
the mortality increase in our meta-analysis might be due 
to chance, it could also indicate an excess of deaths 
attributed to non-cardiovascular causes (for example, 
cancer related deaths, as observed in the large DAPT 
trial10 19) or to major bleeding.
limitations
The results were analysed on trial level data and not on 
patient level data; individual patient information 
would have added further insights to the analysis. Fur-
thermore, the criteria for inclusion of patients in this 
meta-analysis were broad, comprising both stable low 
risk and unstable high risk patients, according to the 
original trial designs, and reflecting more closely the 
case mix encountered in clinical practice. Different 
types of P2Y12 antagonists (clopidogrel, prasugrel, and 
ticagrelor) and drug eluting stents were used across and 
within trials. These data should be viewed as reflecting 
real world routine practice in all patients treated with 
different antiplatelet drugs and drug eluting stents, 
based on clinical settings, operator choices, and drug 
availability.
On the other hand, all the main and sensitivity anal-
yses performed were consistent, suggesting that the 
effects of the different durations of dual antiplatelet 
therapy were robust and justified. Since most ran-
domised trials were performed under clopidogrel, and 
first generation drug eluting stents were implanted in a 
sizable fraction of patients, further randomised con-
trolled trials are needed to explore the effect of novel 
P2Y12 inhibitors and new stents on the duration of dual 
antiplatelet therapy. Finally, no data were available to 
specifically test the interaction of different stents and 
different DAPT durations.
Conclusions
Discontinuation of dual antiplatelet therapy before the 
recommended 12 month period following percutaneous 
coronary intervention with drug eluting stents yields 
significantly reduced bleeding without increasing isch-
aemic outcomes. By contrast, dual antiplatelet therapy 
maintained well beyond 12 months (that is, up to 24 or 
30 months) reduces the incidence of thrombotic com-
plications, in particular stent thrombosis and myocar-
dial infarction, at the price of increased major bleeding 
and possibly all cause death. The effect of extended 
dual antiplatelet therapy on mortality rates observed in 
the DAPT trial10 19 and confirmed in this meta-analysis 
remains preliminary, as a play of chance cannot be 
excluded. However, this observation warrants further 
investigation as, if true, could have profound conse-
quences on public health.
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